Deakin University
Browse

Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma.

Version 2 2024-06-06, 05:21
Version 1 2023-06-07, 01:47
conference contribution
posted on 2024-06-06, 05:21 authored by Elizabeth J Hovey, Kathryn Maree Field, Mark Rosenthal, Anna K Nowak, Lawrence Cher, Helen Wheeler, Elizabeth Barnes, Pramit Phal, Ann LivingstoneAnn Livingstone, Kate Sawkins, John Simes
Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma.

History

Journal

Journal of Clinical Oncology

Volume

33

Pagination

2003-2003

Location

IL, Chicago

Publisher DOI

ISSN

0732-183X

eISSN

1527-7755

Language

en

Author URL

Publication classification

E3.1 Extract of paper

Title of proceedings

Journal of Clinical Oncology

Issue

15_suppl

Publisher

American Society of Clinical Oncology (ASCO)

Publication URL

Usage metrics

    Research Publications

    Categories

    Keywords

    Uncategorised value

    Licence

    All Rights Reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC